



NDA 204736

**NDA APPROVAL
FULFILLMENT OF POSTMARKETING
REQUIREMENT**

Eisai Inc.
Attention: Amanda Goodwin
Associate Director, Regulatory Affairs
155 Tice Boulevard
Woodcliff Lake, NJ 07677

Dear Ms. Goodwin:

Please refer to your New Drug Application (NDA) dated and received September 27, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for AcipHex[®] Sprinkle[™] (rabeprazole sodium) Delayed-Release Capsules, 5mg and 10mg.

We acknowledge receipt of your amendments dated October 26, 2012, November 27, 2012, December 7, 2012, December 28, 2012, January 10, 2013, January 15, 2013, February 1, 2013, February 11, 2013, February 15, 2013, February 27, 2013, March 6, 2013, March 13, 2013, March 22, 2013, and March 25, 2013.

This new drug application provides for the use of AcipHex[®] Sprinkle[™] (rabeprazole sodium) Delayed-Release Capsules for the treatment of gastroesophageal reflux disease (GERD) in pediatric patients 1 year to 11 years of age.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE-CONTAINER LABELS

Submit final printed carton and immediate-container labels that are identical to the enclosed carton and immediate-container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 204736.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

ADVISORY COMMITTEE

Your application for rabeprazole sodium was not referred to an FDA advisory committee because this drug is not the first in its class. Additionally, outside expertise was not necessary; there were no controversial issues that would benefit from advisory committee discussion.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

The product is appropriately labeled for use in ages 12 to 16 years for this indication. Therefore, no additional studies are needed in this pediatric group.

We note that you have fulfilled the pediatric study requirement for ages 0 to 11 years in this application. Therefore, this application, in conjunction with NDA 20973/S022 approved on June 30, 2008, fulfills the following postmarketing requirement listed in the NDA 20973/S009 supplemental approval letter dated February 12, 2002:

1776-1 We are deferring submission of your pediatric studies for the treatment of symptomatic gastroesophageal disease (GERD) until December 31, 2005.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitment:

2024-1 Conduct an in vitro study to assess the effect of alcohol on the drug release of AcipHex[®] Sprinkle[™] Delayed Release Capsules.

The timetable you submitted on March 15, 2013, states that you will conduct this study according to the following schedule:

Final Protocol Submission: May 2013
Study Completion: July 2013
Final Report Submission: August 2013

Submit clinical protocols to your IND 33985 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “**Postmarketing Commitment Protocol,**” “**Postmarketing Commitment Final Report,**” or “**Postmarketing Commitment Correspondence.**”

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call CDR Stacy Barley, Senior Regulatory Project Manager, at (301) 796-2137.

Sincerely,

{See appended electronic signature page}

Andrew E. Mulberg, M.D., F.A.A.P., C.P.I.
Deputy Director
Division of Gastroenterology and Inborn
Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure(s):
Content of Labeling
Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ANDREW E MULBERG
03/26/2013